Cardio-toxicity among patients with sarcoma: a cardio-oncology registry

Sivan Shamai, Sivan Shamai, Zach Rozenbaum, Zach Rozenbaum, Ofer Merimsky, Ofer Merimsky, Matthew Derakhshesh, Yonatan Moshkovits, Joshua Arnold, Yan Topilsky, Yan Topilsky, Yaron Arbel, Yaron Arbel, Michal Laufer-Perl*, Michal Laufer-Perl*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Background: Chemotherapy induced cardio-toxicity has been recognized as a serious side effect since the first introduction to anthracyclines (ANT). Cardio-toxicity among patients with breast cancer is well studied but the impact on patients with sarcoma is limited, even though they are exposed to higher ANT doses. The commonly used term for cardio-toxicity is cancer therapeutics related cardiac dysfunction (CTRCD), defined as a left ventricular ejection fraction (LVEF) reduction of > 10%, to a value below 53%. The aim of our study was to estimate the prevalence of CTRCD in patients diagnosed with sarcoma and to describe the baseline risk factors and echocardiography parameters among that population. Methods: Data were collected as part of the Israel Cardio-Oncology Registry (ICOR), enrolling all patients evaluated in the cardio-oncology clinic at our institution. The registry was approved by the local ethics committee and is registered in clinicaltrials.gov (Identifier: NCT02818517). All sarcoma patients were enrolled and divided into two groups - CTRCD group vs. non-CTRCD group. Results: Among 43 consecutive patients, 6 (14%) developed CTRCD. Baseline cardiac risk factors were more frequent among the non-CTRCD group. Elevated left ventricular end systolic diameter and reduced Global Longitudinal Strain were observed among the CTRCD group. During follow-up, 2 (33%) patients died in the CTRCD group vs. 3 (8.1%) patients in the non-CTRCD group. Conclusions: CTRCD is an important concern among patients with sarcoma, regardless of baseline risk factors. Echocardiography parameters may provide an early diagnosis of cardio-toxicity.

Original languageEnglish
Article number609
JournalBMC Cancer
Volume20
Issue number1
DOIs
StatePublished - 30 Jun 2020

Keywords

  • CTRCD
  • Cardiotoxicity
  • Echocardiography
  • GLS
  • Sarcoma

Fingerprint

Dive into the research topics of 'Cardio-toxicity among patients with sarcoma: a cardio-oncology registry'. Together they form a unique fingerprint.

Cite this